Table 4.

Association between htSNPs in candidate steroidogenic pathways and all-cause mortality following ADT in the Asian cohort (n = 601)

All-cause mortality
ACMHeterozygotesHomozygotesBest-fitting genetic models
SNPMajorMinorMAFDeadAliveHR (95% CI)PHR (95% CI)PModelHR (95% CI)P
CYP17A1
 rs1004467TTCC33%15/59/5940/196/1770.94 (0.65–1.37)0.750.78 (0.43–1.42)0.42DOM0.91 (0.63–1.29)0.58
 rs2486758TTCC22%7/47/8017/148/2460.96 (0.66–1.38)0.811.87 (0.85–4.11)0.12REC1.90 (0.87–4.13)0.10
 rs6162AAGG47%34/66/3485/207/1201.24 (0.80–1.92)0.351.69 (1.03–2.78)0.037REC1.49 (0.99–2.25)0.06
 rs743572GGAA47%32/65/3684/206/1171.13 (0.73–1.74)0.591.53 (0.93–2.52)0.10REC1.42 (0.93–2.17)0.10
CYP19A1
 rs1870050AACC29%7/51/7639/174/2000.72 (0.50–1.04)0.080.57 (0.26–1.25)0.16DOM0.70 (0.49–1.00)0.048
 rs2446404AAGG3%0/7/1271/29/382DOM0.55 (0.24–1.28)0.17
ESR1
 rs1062577TTAA24%9/52/7223/144/2491.42 (0.98–2.06)0.061.68 (0.82–3.41)0.15DOM1.45 (1.02–2.07)0.038
 rs2982683CCTT18%2/41/9111/127/2750.90 (0.61–1.32)0.580.99 (0.24–4.08)0.99REC1.03 (0.25–4.21)0.97
 rs3003922GGCC46%24/69/3875/226/1071.11 (0.73–1.68)0.631.10 (0.64–1.88)0.73DOM1.11 (0.74–1.64)0.62
 rs488133CCTT7%1/16/1170/54/356DOM0.66 (0.38–1.14)0.14
 rs9341016TTCC14%2/36/9312/85/3101.00 (0.67–1.49)0.991.52 (0.37–6.34)0.56REC1.52 (0.37–6.32)0.56
 HSD17B2
 rs4243229GGAA20%9/48/7615/123/2731.73 (1.19–2.51)0.0041.96 (0.87–4.38)0.10DOM1.75 (1.22–2.51)0.002
 rs7201637TTAA18%4/33/9713/130/2700.65 (0.43–0.98)0.0411.13 (0.41–3.10)0.82DOM0.68 (0.46–1.02)0.06
 rs9934209GGCC44%25/68/4177/211/1261.06 (0.70–1.59)0.791.21 (0.72–2.03)0.47REC1.17 (0.74–1.84)0.50
HSD17B3
 rs10739847AATT41%22/60/5073/191/1441.03 (0.70–1.52)0.890.95 (0.56–1.62)0.85REC0.94 (0.58–1.51)0.79
 rs1810711GGTT41%21/66/4760/214/1370.87 (0.59–1.29)0.501.08 (0.64–1.83)0.76REC1.18 (0.73–1.88)0.50
 rs2257157TTCC35%14/76/4452/180/1811.72 (1.17–2.52)0.0051.14 (0.61–2.15)0.68DOM1.60 (1.11–2.33)0.013

NOTE: For SNPs in HSD17B2 (rs1119933, rs1364287, rs2955162, and rs8059915), frequency of minor-allele homozygotes was too low to compute HRs in the recessive model as previously described in Caucasians (17). P < 0.05 are indicated in bold. HRs were adjusted for age, TNM staging, Gleason score, PSA at ADT initiation, PSA nadir, time to PSA nadir, and treatment modality as described in the Materials and Methods section. When the frequency of rare minor-allele homozygotes was 2% or less, they were combined with heterozygotes. For these SNPs, values were not computed for heterozygotes or minor-allele homozygotes, and corresponding boxes are in gray. Bold, significant P values.

Abbreviations: DOM, dominant model; REC, recessive model.